Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rhabdoid Tumor 1Pancreatic Adenocarcinoma 1Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Esophageal Neoplasms 1Endometrial Neoplasms 1Chordoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Liver Cancers 1

Interventions

tocilizumab 1selicrelumab 1niraparib 1durvalumab 1cobimetinib 1atezolizumab 1Tiragolumab 1Panitumumab 1PEGPH20 1Oxaliplatin 1Optical Imaging 1Nivolumab 1Leucovorin 1Ipilimumab 1Gemcitabine 1Fluorouracil 1Bevacizumab 14-fluorobenzoyl-TN-14003 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Adenocarcinoma × Tiragolumab × Clear all
NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
341 enrolled 28 charts
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡